bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
Health Care · Biotechnology · US
$0.40
-0.52% today · -94.7% 1Y
bioAffinity Technologies, Inc. (NasdaqCM: BIAF) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.24M and employs 57 people.
Over the last twelve months the share price has lost 94.7%, trading between 0.33 and 13.50.
Tweenvest scores bioAffinity Technologies, Inc. across four factors: quality 26/100, value 40/100. Its strongest factor is value.
BIAF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.24M
- Revenue (TTM)
- $5.90M
- P/E
- —
- EPS
- -3.98
- Dividend yield
- —
- Beta (5Y)
- -1.05
- 52-week high
- $13.50
- 52-week low
- $0.33
- Avg volume (3M)
- —
- Shares outstanding
- 8.10M
- Employees
- 57
- Next earnings
- —
About bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
- Founded
- 2014
- Listed since
- Sep 1, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.